Literature DB >> 32491977

On construction of smallest one-sided confidence intervals for the response rate in adaptive two- or multi-stage designs.

Weizhen Wang1,2, Huan Yin1, Zhongzhan Zhang1.   

Abstract

To assess the effectiveness of a treatment in phase II clinical trial for cancer study, an adaptive multi-stage design, especially a two-stage one, is commonly used. This type of design allows an on-going study to end early for the participant's safety and design's efficiency. Since a large value of the response rate p for the treatment is wanted, lower one-sided confidence intervals for p are of interest. Due to the limited sample size, exact intervals with a guaranteed confidence level are derived using a rank function that is based on the Clopper-Pearson lower confidence limit. When the sample size in stage 2 is a constant, two kinds of smallest intervals are constructed with or without using the sufficiency principle. The proposed intervals outperform the existing exact intervals, and the intervals not based on minimal sufficient statistic are recommended for practice due to their small expected lengths. When the sample size in stage 2 varies, the smallest interval is also proposed.

Entities:  

Keywords:  Clopper–Pearson interval; coverage probability; lower one-sided confidence limit; phase II clinical trial; sufficiency principle

Mesh:

Year:  2019        PMID: 32491977     DOI: 10.1177/0962280219873359

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  1 in total

1.  Brief Report: Financial Incentives and Real-Time Adherence Monitoring to Promote Daily Adherence to HIV Treatment and Viral Suppression Among People Living With HIV: A Pilot Study.

Authors:  Cedric H Bien-Gund; Joshua I Ho; Elizabeth F Bair; Noora Marcus; Rebekah Ji Choi; Zsofia Szep; Amy Althoff; Florence M Momplaisir; Harsha Thirumurthy
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.